Neurocrine Biosciences Inc

Most Recent

  • uploads///Graph Part
    Company & Industry Overviews

    Incyte and Neurocrine Trade above 100-Day Moving Averages

    On September 4, 2015, Incyte (INCY) closed trading at $115.88 and continued to trade above 20-day, 50-day, and 100-day moving averages. The stock outperformed the IBB.

    By Peter Neil
  • uploads///Graph Part  Dec
    Company & Industry Overviews

    Ultragenyx Woos Investors with Good Returns in Mid-Cap Space

    Ultragenyx Pharmaceutical (RARE) rebounded on December 14, 2015, after falling for four consecutive days. The stock rose 3.8% and was the top performer among the mid-cap stocks that day.

    By Peter Neil
  • uploads///Graph Part
    Company & Industry Overviews

    SPDR S&P Biotech ETF (XBI) Had a Mixed Day on October 8

    The SPDR S&P Biotech ETF (XBI) had a mixed day on October 8, 2015. Of the 101 holdings, 32 stocks ended up in green, and 69 stocks ended up in red. But overall, XBI fell 1.0% for the day.

    By Peter Neil
  • uploads///Graph Part  Oct
    Company & Industry Overviews

    Anacor Underperformed the Top 10 Pharmaceutical Subgroup Stocks

    Anacor Pharmaceuticals fell by 6.8% due to profit-booking. It had ~650,000 shares being traded. It closed at $107.17. It breached the 100-day moving average.

    By Peter Neil
  • uploads///Graph Part
    Company & Industry Overviews

    Biotech Stocks Hammered Badly Last Week after Clinton Comment

    Last week was an unforgettable week for biotech stocks. It began on a bad note after Hillary Clinton commented on price controls for the specialty drug market, which created panic and triggered a sell-off.

    By Peter Neil
  • uploads///Graph
    Earnings Report

    Neurocrine Biosciences Has Robust Late-Stage Pipeline

    According to Neurocrine Biosciences’ first-quarter earnings investor presentation, the company expects to have a portfolio of three assets approved across four indications by the end of fiscal 2020.

    By Margaret Patrick
  • uploads///utah _
    Company & Industry Overviews

    Why Is Voyager Therapeutics Soaring Today?

    Today, Voyager Therapeutics (VYGR) issued a press release announcing a strategic collaboration with Neurocrine Biosciences (NBIX).

    By Margaret Patrick
  • uploads///brain _
    Company & Industry Overviews

    Why Neurocrine Biosciences Stock Rose 9.6% Yesterday

    On January 7, Neurocrine Biosciences (NBIX) stock rose ~9.57% to reach $81.86 from its prior close of $74.71.

    By Daniel Collins
  • uploads///blood _
    Company & Industry Overviews

    Why Neurocrine Biosciences Stock Is Plummeting Today

    Today, Neurocrine Biosciences (NBIX) is trading at $67.91, a ~20.83% fall from its closing price of $85.76 on December 11.

    By Daniel Collins
  • uploads///blood _
    Earnings Report

    Alkermes in the Third Quarter: A Performance Overview

    Alkermes (ALKS) reported its third-quarter results on October 23. It generated net revenues of $248.7 million, a 14% YoY growth.

    By Daniel Collins
  • uploads///NBIX
    Company & Industry Overviews

    Analysts Are Mostly Positive on Neurocrine Biosciences

    On October 4, Neurocrine Biosciences (NBIX) stock closed at $114.58, which is an ~3.79% decline from its October 3 close of $119.09.

    By Daniel Collins
  • uploads///IONS
    Company & Industry Overviews

    A Financial Overview of Ionis Pharmaceuticals in October

    Ionis Pharmaceuticals generated Q2 2018 revenues of $118.0 million compared to $122.3 million in Q2 2017, which reflected ~15.0% YoY growth.

    By Daniel Collins
  • uploads///Supernus
    Company & Industry Overviews

    A Financial Overview of Supernus Pharmaceuticals in September

    In Q2 2018, Supernus Pharmaceuticals (SUPN) reported net revenues of $99.5 million compared to $75.8 million in Q2 2017.

    By Daniel Collins
  • uploads///pill _
    Company & Industry Overviews

    Supernus Pharmaceuticals Garners 89% ‘Buy’ Ratings in September

    Of the nine analysts tracking Supernus Pharmaceuticals (SUPN), three recommended a “strong buy” while five analysts recommended a “buy.”

    By Daniel Collins
  • uploads///drugs _
    Company & Industry Overviews

    Why Tonix Pharmaceuticals Stock Soared Today

    Today, Tonix Pharmaceuticals (TNXP) was trading at $4.23, which represents ~7.09% growth from yesterday’s close of $3.95.

    By Daniel Collins
  • uploads///syringe _
    Company & Industry Overviews

    Analysts Are Mostly Positive on Exelixis in July

    On July 3, Exelixis (EXEL) stock closed at $21.4, a ~15.7% increase from its 52-week low of $18.5 on May 10.

    By Daniel Collins
  • uploads///cell
    Company & Industry Overviews

    Why Actinium Pharmaceuticals Stock Rose 25.6% on June 18

    On June 18, Actinium Pharmaceuticals (ATNM) stock rose ~25.6% to reach $0.63.

    By Daniel Collins
  • uploads///versartis
    Company & Industry Overviews

    Versartis Stock and Its Consistent Rise in the Week Ended June 8

    Versartis (VSAR) stock rose 48.3% in the week of June 1–8. On June 8, it closed at $2.15.

    By Daniel Collins
  • uploads///Ingrezza
    Fund Managers

    Ingrezza: Boosting Neurocrine’s Top Line

    Neurocrine Biosciences’ primary focus is on neurological and endocrine-based diseases and disorders. Its leading product is Ingrezza.

    By Kenneth Smith
  • uploads/// business line revenue
    Company & Industry Overviews

    How Is Teva Progressing with Its Specialty Assets Portfolio?

    Teva Pharmaceutical (TEVA) is focused on advancing its specialty assets portfolio, one of its key growth drivers.

    By Sarah Collins
  • uploads///Cara SGA
    Company & Industry Overviews

    Comparing Cara Therapeutics’ Financial Performance

    Financial performance In 3Q17, Cara Therapeutics (CARA) incurred $9.6 million in research and development expenses, compared with $9.1 million in 3Q16. This fall in expenses was due to a $3.1 million decrease in expenses for oral CR845’s Phase 2B clinical trial, and partially offset by increased expenses for its intravenous CR845 safety study. Meanwhile, the company’s general and administrative expenses rose from […]

    By Kenneth Smith
  • uploads///oral CR
    Company & Industry Overviews

    Cara Therapeutics’ Collaboration Agreements

    Oral CR845 for treating chronic kidney disease–associated pruritus In July 2017, Cara Therapeutics (CARA) announced the results from a Phase 1 safety and pharmacokinetics study of oral CR845 in patients with chronic kidney disease (or CKD) undergoing hemodialysis. The results showed that the four dosage strengths evaluated in the study were well tolerated. In October […]

    By Kenneth Smith
  • uploads///Cara Analysts reco
    Company & Industry Overviews

    Analysts’ Recommendations for Cara Therapeutics in January 2018

    Cara Therapeutics (CARA) is a clinical-stage biopharmaceutical company focused on developing and commercializing chemical entities designed to alleviate pain and pruritus.

    By Kenneth Smith
  • uploads///Graph
    Company & Industry Overviews

    Elagolix May Advance the Treatment Paradigm in Women’s Health

    On October 27, 2017, AbbVie (ABBV) announced that the New Drug Application for its investigational drug Elagolix had been granted priority review by the FDA.

    By Margaret Patrick
  • uploads///Bioverativ
    Company & Industry Overviews

    Analysts’ Recommendations for Bioverativ in January 2018

    Fourteen analysts were tracking Bioverativ in January 2018. Four analysts recommended “strong buys,” while two recommended “buys” on the stock.

    By Daniel Collins
  • uploads///Graph
    Company & Industry Overviews

    Geographic Market Expansion to Boost Spinraza Sales in 2017

    In 3Q17, Biogen (BIIB) and Ionis Pharmaceuticals’ (IONS) Spinraza reported sales worth $73 million from international markets.

    By Margaret Patrick
  • uploads///Analysts Ratings
    Company & Industry Overviews

    Behind Bioverativ’s Analyst Recommendations This September

    Of the 12 analysts tracking Bioverativ (BIVV), three recommend a “strong buy” for the stock, while one recommends a “buy,” and seven recommend a “hold.”

    By Daniel Collins
  • uploads///Neurocrine Analysts reco
    Company & Industry Overviews

    Neurocrine Biosciences: Ingrezza, Collaborations, Ratings

    In April 2017, the FDA approved Neurocrine Biosciences’ (NBIX) Ingrezza (valbenazine) as the first drug for the treatment of tardive dyskinesia.

    By Daniel Collins
  • uploads///Graph
    Company & Industry Overviews

    Uterine Fibroids Segment May Offer Opportunity for NBIX

    According to MarketScan and Truven Health Analytics, approximately 9 million women in the US need therapy for symptoms related to uterine fibroids (or UF).

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Neurocrine Biosciences Pursues Women’s Health Segment with Elagolix

    While Neurocrine Biosciences (NBIX) invented and developed Elagolix until Phase 2 trials, it is currently being tested in Phase 3 trials by AbbVie (ABBV).

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Why Valbenazine Studies Seem Promising

    In Neurocrine Biosciences’ (NBIX) phase three trial Kinect-3, investigational therapy Valbenazine has managed to demonstrate statistically significant improvement.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Why Neurocrine Biosciences May See Higher Losses in 2016

    Wall Street analysts have projected that Neurocrine Biosciences’ net income in 2016 will be -$146.2 million, a significantly higher loss than in 2015.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Clinical Trial Data Shows Efficacy of Elagolix to Treat Uterine Fibroids

    Together, AbbVie (ABBV) and Neurocrine Biosciences (NBIX) aim to develop Elagolix as a minimally invasive yet effective therapy for uterine fibroids

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Phase 3 Trials Show Elagolix’s Efficacy for Endometriosis Pain

    AbbVie (ABBV) and Neurocrine Biosciences (NBIX) have completed two phase 3 trials to evaluate the efficacy and safety of Elagolix as a treatment option for reducing pain associated with endometriosis as compared to a placebo.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Elagolix May Become a Leading Uterine Fibroids Drug

    In addition to endometriosis, AbbVie’s (ABBV) and Neurocrine Biosciences’s (NBIX) Elagolix is also being investigated as a therapy for uterine fibroids.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Elagolix May Become a Strong Growth Driver for AbbVie

    On October 19, 2016, AbbVie (ABBV) and Neurocrine Biosciences (NBIX) announced positive results from two phase 3 clinical trials at the 72nd American Society for Reproductive Medicine Scientific Congress & Expo.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    AbbVie Expects Investigational Drug Elagolix to Be a Blockbuster

    Due to significant unmet demand and limited competition in the women’s health segment, AbbVie expects Elagolix to become a blockbuster therapy.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Positive Top-Line Data May Help Secure FDA Approval for Valbenazine

    Neurocrine Biosciences has seen positive results from Kinect 3, a phase-3 trial that tested the efficacy and safety of Valbenazine for tardive dyskinesia.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Inside Neurocrine Biosciences’ Analyst Recommendations in 2016

    Based on the recommendations of eight brokerage firms, a Bloomberg survey reported that 100% of analysts gave Neurocrine Biosciences “buy” recommendations.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Neurocrine Biosciences’ Valbenazine Launch: What You Need to Know

    Neurocrine Biosciences (NBIX) expects to submit a new drug application to the FDA for Valbenazine in 2016.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Will Elagolix Make Neurocrine Biosciences a Key Women’s Health Name?

    If approved, Elagolix could present fierce competition for existing drugs like Teva Pharmaceuticals’ (TEVA) Aygestin and Astrazeneca’s (AZN) Zoladex.

    By Margaret Patrick
  • uploads///Part  Graph
    Company & Industry Overviews

    XBI Mid-Cap News: Look Who Took a Beating on March 23

    Among the 18 mid-cap stocks that XBI holds in its portfolio, 17 declined and only one advanced on March 23. Mid-caps represent ~30% of XBI’s portfolio.

    By Peter Neil
  • uploads///Graph Part
    Company & Industry Overviews

    ICPT and XON Put Pressure on XBI’s Biotechnology Sector

    Intrexon (XON) plummeted by 14.4% after it announced its 2Q15 results. As per the company’s press release, XON’s total revenue was $44.9 million.

    By Peter Neil
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.